Targeting menin induces responses in acute leukemias with KMT2A rearrangements or NPM1 mutations
Researchers from Â鶹ӳ» MD Anderson Cancer Center showed that inhibiting menin with revumenib, previously known as SNDX-5613, yielded encouraging responses for advanced acute leukemias with KMT2A rearrangements or mutant NPM1. Findings from the Phase I AUGMENT-101 trial were published today in Nature.
The overall response rate among 60 patients was 53%, and the rate of complete remission or complete...
MD Anderson Research Highlights: ASH 2022 Special Edition
ABSTRACTS 62, 82, 95, 199, 232, 540, 708, 766, 960
Â鶹ӳ» MD Anderson Cancer Center’s Research Highlights provides...
MD Anderson Research Highlights: SABCS 2022 Special Edition
ABSTRACTS GS1-07, GS5-08, PD6-11, HER2-01
Â鶹ӳ» MD Anderson Cancer Center’s Research Highlights provides a glimpse...